Actonel/Risedronate Daily

Osteoporosis is often described as a silent condition. Bone density declines gradually, without pain or obvious symptoms, until a fracture occurs. For patients whose prescriber recommends a daily dosing regimen rather than a weekly or monthly schedule, Actonel/Risedronate Daily 5mg Tablets offer a clinically established option within the bisphosphonate class. Risedronate sodium is a once-daily oral tablet prescribed for the treatment and prevention of osteoporosis, and for the prevention of osteoporosis in postmenopausal women at elevated risk of fracture.

The daily 5mg regimen is specifically indicated where a daily schedule is considered more appropriate than the alternatives. This may apply in the context of glucocorticoid-induced osteoporosis, in patients following particular clinical pathways, or where a prescriber judges a daily regimen better suited to an individual's circumstances. A clinical consultation with a registered prescriber is required before any supply can take place.

Actonel is the branded version of risedronate sodium, and risedronate daily 5mg tablets are its generic equivalent. Both contain the same active ingredient at the same dose and are therapeutically interchangeable. Risedronate sodium belongs to the bisphosphonate class of medicines, which work directly on bone tissue to slow the process of bone loss.

The 5mg daily formulation is distinct from the more commonly prescribed 35mg once-weekly risedronate tablet. While both contain the same active ingredient, the daily formulation delivers a lower dose each day and has its own licensed indications, which include the treatment of osteoporosis in postmenopausal women, the treatment of osteoporosis in men at risk of fracture, and the prevention and treatment of glucocorticoid-induced osteoporosis in men and women.

Glucocorticoid-induced osteoporosis deserves particular mention. Long-term use of corticosteroids – medicines such as prednisolone prescribed for conditions including rheumatoid arthritis, inflammatory bowel disease, and respiratory conditions – is one of the most common secondary causes of osteoporosis. Risedronate 5mg daily is one of the options recommended in clinical guidelines for protecting bone health in patients on sustained corticosteroid therapy.

This medicine is a Prescription Only Medicine. Its use must be assessed and approved by a registered prescriber on the basis of an individual's clinical profile.

Bone is not static. Throughout life, the skeleton continuously remodels itself through a tightly regulated cycle: bone resorption by osteoclast cells removes old or damaged bone, and bone formation by osteoblast cells deposits new mineralised tissue in its place. In healthy adults, this cycle is balanced. In osteoporosis, resorption outpaces formation, and the net result is progressive weakening of the skeletal structure.

Risedronate sodium binds to the mineral surface of bone with high affinity. Once incorporated into bone at sites of active resorption, it is taken up by osteoclasts during the bone breakdown process. Inside the osteoclast, risedronate disrupts an internal signalling enzyme, causing the cell to become less active and eventually undergo programmed cell death. The rate of bone resorption slows substantially as a result.

This mechanism is shared across the bisphosphonate class, but different bisphosphonates vary in their binding affinity and potency at the molecular level. Risedronate has a relatively rapid offset of binding compared to some other bisphosphonates, which has implications for the reversibility of its effects and for the behaviour of the bone remodelling cycle during and after treatment.

Clinical evidence supports risedronate's ability to increase bone mineral density at the lumbar spine, femoral neck, and total hip over time, and to reduce the incidence of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis. In the context of glucocorticoid-induced bone loss, risedronate has also demonstrated fracture risk reduction in clinical trials, supporting its use in this specific patient group.

Take one risedronate 5mg tablet by mouth once daily. The tablet should be swallowed whole with a full glass of plain tap water, at least 200ml, while you are standing or sitting upright. Do not crush, split, or chew the tablet.

Take the tablet at least thirty minutes before the first food, drink other than plain water, or other oral medicine of the day. This absorption window is critical. The oral bioavailability of risedronate is low under the best of conditions, and the presence of food, coffee, tea, juice, dairy products, or most other beverages in the stomach will reduce absorption further. Mineral water is not recommended for taking the tablet, as the mineral content can impair absorption.

After taking the tablet, remain upright – either standing or sitting – for at least thirty minutes. Do not lie down during this period. This reduces the risk of the tablet causing localised irritation or ulceration of the oesophageal lining. Do not take the tablet at bedtime or before rising from bed.

If you miss a dose on a given day, take it on the morning of the following day and then return to your usual daily schedule. Do not take two tablets on the same day to compensate for a missed dose. If you vomit shortly after taking the tablet, do not take a replacement dose. Continue with your scheduled dose the following morning and inform your prescriber if vomiting is a persistent problem.

Risedronate must not be taken at the same time as calcium supplements, antacids, or other medicines containing calcium, magnesium, aluminium, or iron. These should be taken at a different time of day, at least two hours apart from risedronate, to avoid interference with absorption.

Licensed Formulation for Daily Use

This product page covers the 5mg daily formulation of risedronate sodium. The table below summarises the dosing schedule for this specific formulation.

Risedronate in Other Dosing Schedules

Risedronate sodium is also available in a 35mg once-weekly tablet and a 75mg two-consecutive-day-per-month formulation (Actonel Combi). These are separate products with their own licensed indications and prescribing considerations. They are not covered by this product page. If you have been prescribed one of those formulations, refer to the relevant product page or speak to your pharmacist.

Duration of Treatment

Treatment with risedronate for osteoporosis is typically long term. Clinical benefit accumulates over time, and ongoing use is necessary to maintain the protective effect on bone. Prescribers generally review bisphosphonate therapy periodically – commonly after three to five years – to reassess the benefit-to-risk balance for each individual patient. Do not stop taking the tablets without first consulting your prescriber.

Take risedronate exactly as prescribed. Do not alter the dose or frequency without speaking to your prescriber first.

Risedronate 5mg is generally well tolerated in clinical practice. As with all medicines, side effects can occur, and the following information is based on the UK Summary of Product Characteristics for this formulation.

Common Side Effects (may affect up to 1 in 10 people)

1. Abdominal pain, nausea, or indigestion
2. Diarrhoea or constipation
3. Headache
4. Musculoskeletal pain, including bone, joint, or muscle ache
5. Dysphagia (difficulty swallowing)

Uncommon Side Effects (may affect up to 1 in 100 people)

1. Oesophagitis or oesophageal ulceration
2. Gastritis or gastric ulcer
3. Skin rash or pruritus (itching)
4. Low calcium levels in the blood (hypocalcaemia), particularly where vitamin D deficiency is present
5. Iritis or uveitis (inflammation within the eye)

Rare but Clinically Important Adverse Effects

The following adverse effects are rare but have been reported with risedronate and other bisphosphonates. Patients should be aware of them and seek medical advice promptly if they develop.

1. Osteonecrosis of the jaw (ONJ): deterioration of jaw bone, most commonly associated with invasive dental procedures in patients on bisphosphonate therapy. Inform your dentist that you are taking risedronate before any dental work, including extractions.
2. Atypical subtrochanteric and diaphyseal femoral fractures: unusual stress fractures of the thigh bone reported with long-term bisphosphonate use. New or unusual thigh, hip, or groin pain should be reported to your prescriber promptly, even if it develops gradually.
3. Severe skin reactions, including Stevens-Johnson syndrome (very rare)

Musculoskeletal pain, including bone pain and joint stiffness, can occasionally be severe. If you experience significant new pain after starting risedronate, inform your prescriber.

Report any side effects directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk, or through your prescriber or pharmacist.

Suitable Patients

Risedronate 5mg daily is licensed for adults, including postmenopausal women with osteoporosis, men at increased risk of fracture, and patients of either sex who require bone protection during or after long-term glucocorticoid therapy. It is particularly relevant for patients whose clinical circumstances or prescriber preference favours a daily dosing schedule over the once-weekly or monthly alternatives available in the risedronate range.

Suitability is determined on an individual basis through clinical consultation. A history of bone density measurement, fracture risk assessment, relevant medical conditions, and concurrent medications will all form part of the prescriber's assessment.

Who Should Not Take Risedronate 5mg Daily

Risedronate 5mg daily should not be taken by patients with any of the following.

1. Hypocalcaemia that has not been corrected prior to starting treatment
2. Severe renal impairment (creatinine clearance below 30ml per minute)
3. Known hypersensitivity to risedronate sodium or any of the tablet's excipients
4. Inability to stand or sit upright for at least thirty minutes after taking the dose
5. Oesophageal abnormalities that delay emptying, such as stricture or achalasia

Women who are pregnant or breastfeeding should not take risedronate. The medicine is not licensed for use in children or adolescents. Patients with mild to moderate renal impairment can take risedronate, but should inform their prescriber so that renal function can be monitored appropriately.

Patients taking corticosteroids long term should ensure their prescriber is aware of all medicines they are receiving. The combination of corticosteroid use and bisphosphonate therapy is clinically managed, but accurate reporting of concurrent medicines is essential to safe prescribing.

Risedronate 5mg daily is a Prescription Only Medicine. Completing a clinical consultation is the necessary first step. A prescription may follow from that consultation, but it is not guaranteed. The prescriber will issue a prescription only if they determine that this medicine is appropriate for your individual clinical circumstances.

When you complete a consultation through Pharmacy Planet, you will be asked about your diagnosis, your bone health history, any relevant fractures, concurrent medical conditions, and all medicines you currently take. If you are being treated for a condition that increases your risk of osteoporosis, such as long-term corticosteroid use, inflammatory arthritis, or early menopause, this context will be relevant to the prescriber's decision.

Risedronate treatment for osteoporosis is typically initiated following a confirmed diagnosis, often supported by bone density measurement via a DEXA scan or fracture risk calculation using tools such as FRAX or QFracture. If you are continuing an existing prescription through Pharmacy Planet, the prescriber will confirm that ongoing treatment remains clinically appropriate for you.

If any additional information or clinical investigation is required before a prescribing decision can be made, you will be informed and guided accordingly. Pharmacy Planet's pharmacy team is available to answer questions about the consultation process and about your treatment.

Store risedronate 5mg tablets below 25 degrees Celsius in a dry place. Keep them in the original blister packaging to protect them from moisture and light. Do not transfer tablets to alternative containers unless instructed to do so by your pharmacist.

Keep the tablets out of the sight and reach of children at all times. Do not use tablets beyond the expiry date printed on the blister and carton; the printed date refers to the final day of the stated month.

Return any unused or expired tablets to a pharmacy for safe disposal. Medicines should not be discarded with household waste or flushed into wastewater systems. Your local pharmacy will accept returned medicines free of charge.

All seven medicines listed below are oral tablets or capsules prescribed for osteoporosis, the same therapeutic category and the same form factor, making direct comparison appropriate. They differ in their active ingredient, dosing frequency, licensed indication, and mechanism of action.

The table below compares commonly prescribed oral bisphosphonate treatments available through Pharmacy Planet's osteoporosis service. Products are listed in order of dosing frequency, from daily to monthly, so you can quickly identify how each medicine fits into a patient's routine.

Important: This comparison is for general information only and does not replace medical advice. A prescriber will decide which treatment is suitable for you following an online consultation. All medicines listed are Prescription Only Medicines (POMs). Suitability depends on individual clinical circumstances including diagnosis, renal function, medical history, and concurrent medicines.

Pharmacy Planet is a GPhC-registered online pharmacy providing compliant, patient-centred prescription services across the UK. We operate to the standards required by the General Pharmaceutical Council and dispense all medicines under the supervision of a qualified superintendent pharmacist.

Managing a long-term condition such as osteoporosis requires consistent access to medication and reliable repeat prescribing. Our consultation process is designed to be straightforward for patients who are already established on treatment and are looking for a convenient, regulated pharmacy service for ongoing supply.

Every prescription dispensed by Pharmacy Planet is reviewed by a qualified pharmacist before it is dispatched. Patient safety is at the centre of our clinical and operational processes, and our team is available to answer medication-related questions throughout your care.

1. electronic Medicines Compendium (emc). Actonel 5mg Film-Coated Tablets / Risedronate Sodium 5mg Tablets – Summary of Product Characteristics. www.medicines.org.uk/emc. Accessed June 2026.
2. British National Formulary (BNF). Risedronate sodium. bnf.nice.org.uk/drugs/risedronate-sodium. Accessed June 2026.
3. NHS. Risedronate. www.nhs.uk/medicines/risedronate. Accessed June 2026.
4. National Osteoporosis Guideline Group (NOGG). Clinical Guideline for the Prevention and Treatment of Osteoporosis. www.nogg.org.uk. Accessed June 2026.
5. NICE. Bisphosphonates for treating osteoporosis. Technology appraisal guidance TA160 and updates. www.nice.org.uk/guidance/ta160. Accessed June 2026.